QUÉBEC CITY, QC, Jan. 8, 2014 /CNW Telbec/ - Aeterna Zentaris Inc.
(NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that it has
commenced an underwritten public offering of units (the "Offering"),
consisting of common shares and warrants to purchase common shares. The
pricing and number of Units as well as the exercise price and duration
of the warrants will be determined in the course of marketing.
Canaccord Genuity is acting as sole book-running manager for the
proposed Offering. The proposed Offering is subject to customary conditions, including the
approval of the Toronto Stock Exchange ("TSX") and The NASDAQ Stock
Market ("NASDAQ"), and there can be no assurance as to whether or when
the proposed Offering may be completed, or as to the actual size or
terms of the Offering. The Company has no intention of listing the
warrants on the TSX or NASDAQ.
The Offering is being conducted pursuant to the Company's effective
shelf registration statement on Form F-10 filed with the U.S.
Securities and Exchange Commission (the "SEC"), its corresponding
Canadian base shelf prospectus and an exemption from the Autorité des marches financiers permitting the Company to offer common shares and warrants in the
United States. The proposed offering will be made only by means of a
preliminary prospectus supplement, a final prospectus supplement and
the accompanying short form base shelf prospectus. When available,
copies of the preliminary prospectus supplement, the final prospectus
supplement and the accompanying short form base shelf prospectus may be
obtained upon request by contacting Canaccord Genuity Inc., Attention:
Syndicate Department, 99 High Street, 12th Floor, Boston, Massachusetts
02110, or by telephone at (617) 371-3900. Electronic copies of the
preliminary prospectus supplement, the final prospectus supplement and
the accompanying short form base shelf prospectus will also be
available free of charge at www.sedar.com and www.sec.gov, respectively.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy the securities described herein, nor
shall there be any sale of these securities in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
jurisdiction.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company engaged in
developing novel treatments in oncology and endocrinology. The
Company's pipeline encompasses compounds from drug discovery to
regulatory approval. For more information, visit www.aezsinc.com.
This press release contains forward-looking statements made pursuant to
the safe harbour provisions of the U.S. Securities Litigation Reform
Act of 1995. Forward-looking statements involve known and unknown risks
and uncertainties that could cause the Company's actual results to
differ materially from those in the forward-looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue R&D projects, the successful and timely
completion of clinical studies, the risk that safety and efficacy data
from any of our Phase 3 trials may not coincide with the data analyses
from previously reported Phase 1 and/or Phase 2 clinical trials, the
ability of the Company to efficiently commercialize one or more of its
products or product candidates, the ability of the Company to take
advantage of business opportunities in the pharmaceutical industry,
uncertainties related to the regulatory process and general changes in
economic conditions. Investors should consult the Company's quarterly
and annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to
forward-looking statements. Investors are cautioned not to rely on
these forward-looking statements. The Company does not undertake to
update these forward-looking statements. We disclaim any obligation to
update any such factors or to publicly announce the result of any
revisions to any of the forward-looking statements contained herein to
reflect future results, events or developments, unless required to do
so by a governmental authority or by applicable law.
SOURCE Aeterna Zentaris Inc.